In Reply The Microvascular Outcomes After Metabolic Surgery (MOMS) study demonstrated that Roux-en-Y gastric bypass (RYGB) can be used to place early stages of chronic kidney disease (CKD) in patients with type 2 diabetes into remission.1 Patoulias et al suggested that remission of albuminuria was enhanced by RYGB because more of these patients at baseline received glucagon-like peptide-1 receptor agonist (GLP-1RA). A subanalysis of patients undergoing RYGB according to presurgery treatment with a GLP-1RA found that the treatment did not predict albuminuria response. It should be remembered that GLP-1RA were stopped immediately after RYGB, although metformin, angiotensin-converting enzyme inhibitors, and statins were continued where possible.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Cohen RV, Pereira TV, le Roux CW. The Role of Bariatric Surgery in Prevention of Kidney Disease Progression in Moderately Obese Patients With Type 2 Diabetes—Reply. JAMA Surg. 2021;156(2):206–207. doi:10.1001/jamasurg.2020.5192
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: